133 related articles for article (PubMed ID: 38883641)
1. Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease.
Yamaguchi T; Shimizu J; Shigematsu F; Watanabe N; Hasegawa T; Horio Y; Inaba Y; Fujiwara Y
J Thorac Dis; 2024 May; 16(5):3371-3380. PubMed ID: 38883641
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
3. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Ghazipura M; Mammen MJ; Herman DD; Hon SM; Bissell BD; Macrea M; Kheir F; Khor YH; Knight SL; Raghu G; Wilson KC; Hossain T
Ann Am Thorac Soc; 2022 Jun; 19(6):1040-1049. PubMed ID: 35499854
[No Abstract] [Full Text] [Related]
5. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
6. High resolution computed tomography patterns in interstitial lung disease (ILD): prevalence and prognosis.
Almeida RF; Watte G; Marchiori E; Altmayer S; Pacini GS; Barros MC; Paza Junior A; Runin AS; Salem MCGG; Hochhegger B
J Bras Pneumol; 2020; 46(5):e20190153. PubMed ID: 32159601
[TBL] [Abstract][Full Text] [Related]
7. Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies.
Matsumoto K; Shiroyama T; Kuge T; Miyake K; Yamamoto Y; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
Transl Lung Cancer Res; 2022 Sep; 11(9):1835-1846. PubMed ID: 36248332
[TBL] [Abstract][Full Text] [Related]
8. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
9. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
10. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy.
Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Harada H; Takahashi T
J Cancer; 2018; 9(11):2054-2060. PubMed ID: 29896291
[No Abstract] [Full Text] [Related]
11. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease.
Kato M; Shukuya T; Takahashi F; Mori K; Suina K; Asao T; Kanemaru R; Honma Y; Muraki K; Sugano K; Shibayama R; Koyama R; Shimada N; Takahashi K
BMC Cancer; 2014 Jul; 14():508. PubMed ID: 25012241
[TBL] [Abstract][Full Text] [Related]
12. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.
Yamaguchi T; Shimizu J; Oya Y; Watanabe N; Hasegawa T; Horio Y; Inaba Y; Fujiwara Y
Thorac Cancer; 2022 Mar; 13(5):724-731. PubMed ID: 35044093
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study.
Watanabe T; Minezawa T; Hasegawa M; Goto Y; Okamura T; Sakakibara Y; Niwa Y; Kato A; Hayashi M; Isogai S; Kondo M; Yamamoto N; Hashimoto N; Imaizumi K
BMC Pulm Med; 2019 Nov; 19(1):194. PubMed ID: 31675941
[TBL] [Abstract][Full Text] [Related]
16. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
Petranovic M; McDermott S; Mercaldo S; Little BP; Graur A; Huang K; Fintelmann FJ; Digumarthy SR; Gainor JF
Clin Lung Cancer; 2023 Dec; 24(8):682-688.e5. PubMed ID: 37758549
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody.
Ichihara S; Ogino H; Yoneda H; Haji K; Kagawa K; Murakami K; Mima M; Aoi Y; Mitsuhashi A; Tsukazaki Y; Yabuki Y; Ozaki R; Sato S; Nokihara H; Nishioka Y
Respir Med Case Rep; 2023; 41():101797. PubMed ID: 36583061
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows.
Takahara Y; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Sakuma T; Nishiki K; Nakase K; Nojiri M; Kato R; Shinomiya S; Fujimoto Y; Oikawa T; Mizuno S
Thorac Cancer; 2021 Oct; 12(20):2758-2766. PubMed ID: 34409749
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Clinical Measures Among Interstitial Lung Disease (ILD) Patients with Usual Interstitial Pneumonia (UIP) Patterns on High-Resolution Computed Tomography.
Gibson CD; Bhatt A; Deshwal H; Li X; Goldberg JD; Ko J; Condos R
Lung; 2020 Oct; 198(5):811-819. PubMed ID: 32889595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
